Comparator issue strikes again; Germany's IQWiG in doubt over GSK's Trobalt
This article was originally published in Scrip
Executive Summary
The issue over comparators has cast a shadow over another drug undergoing Germany's early benefit assessment, GlaxoSmithKline/Valeant's Trobalt (retigabine). IQWiG, the Institute for Quality and Efficiency in Healthcare, has said that there is no proof of added benefit for the anti-epileptic after the firm chose different comparators than those wanted by the agency.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.